SAN DIEGO--(BUSINESS WIRE)--BioDuro, LLC, a leading drug discovery and development services organization, announced today the appointment of four senior leadership positions, including David Hedden, Ph.D. (Chief Scientific Officer), Brett Truitt, MS, MBA (Vice President, cGMP Operations), Mohan Thiruvazhi, Ph.D. (Vice President, Business Development), and Raymond Li, CPA, MBA (Vice President, Finance).
“I am truly excited to be part of this exceptional team,” said Cyrus K. Mirsaidi, President and CEO of BioDuro, LLC. “These key additions to the leadership team, augmented by proven track record of our existing executives, supremely positions BioDuro to continue the remarkable growth we have realized over the past 3 years and to fulfill our expectations for our next growth phase, with focus on innovation, quality, and service to our clients, worldwide.”
David Hedden, Ph.D. promoted to Chief Scientific Officer
David will be responsible for the scientific leadership and management of the Formulation and Analytical Development teams as well as provide business development technical support. David brings 32 years of pharmaceutical industry experience, most notably with Pfizer, UPM, Ironwood, Searle/Pharmacia, Sandoz, Dupont, and Adagio, with expertise in pharmaceutics, formulation, process development, and manufacturing for small molecules.
“Since joining BioDuro, it has been exciting to participate in our company’s commitment to quality science,” said Hedden. “I look forward to leading my colleagues in this new position as we continue to innovate in our CDMO operations, and help get much needed medicines to waiting patients.”
Brett Truitt, MS, MBA appointed to Vice President, cGMP Operations
Brett will provide technical and business leadership for BioDuro’s cGMP operations in its next phase of growth. He has 20 years of experience in diverse pharmaceutical environments from early stage companies to industry leading organizations most notably Flatley Discovery Labs, Shire, Pfizer, and Proctor and Gamble. Most recently, he served as Director of Pharmaceutics and Process Technology at Patheon in Cincinnati.
“I am excited to work with BioDuro for the second time in my career – the first as a client responsible for outsourcing to BioDuro an early phase development and manufacturing project of a poorly-soluble drug, and now as a member of the internal team,” said Truitt. “I look forward to supporting BioDuro’s growth in this exciting new phase of the company’s history and providing the same level of outstanding customer service as I experienced as a client.”
Mohan Thiruvazhi, Ph.D. appointed to Vice President, Business Development
Mohan brings to BioDuro a blend of scientific and commercial experience from leading pharma and contract research organizations. He will be responsible for global Business Development efforts in North America, South America, and Europe. Mohan spent a decade at GVK BIO and Syngene International, where he successfully executed US and European strategies to expand geography and client footprints. Prior to that, he ran chemistry operations for six years at ChemBridge Research Labs.
“I look forward to contributing to BioDuro's growth as a premier provider of integrated drug discovery, development, and manufacturing services, through solution-based business development, at a time when it has entered into a financial and strategic partnership with one of the largest and most experienced global private equity investors committed to building value for clients,” said Thiruvazhi.
Raymond Li, CPA, MBA, appointed to Vice President, Finance
Raymond brings a wealth of finance and accounting experience to BioDuro, having served in senior positions at publicly traded, fortune 500 companies (K2 and Emerson Electric), augmented by his experience with having completed IPO preparation for biopharma companies. In his last position as VP of Finance and Operations for Ambrx, Raymond managed all financial reporting to GAAP and IFRS standards and operationally managed full implementation of a global ERP system. Raymond received his master’s in accounting degree from University of Illinois, MBA from Fudan University, and is a licensed and certified CPA in both California and China.
"I am honored to join the BioDuro team at this exciting time and I am delighted for the opportunity to help the organization achieve greater financial results," said Li. "I look forward to building the core financial platforms for BioDuro's significant further growth.”
BioDuro is a leading global life sciences contract research, development and manufacturing organization that provides biopharmaceutical clients and partners with comprehensive, fully integrated drug discovery services spanning target identification to IND filing, through to cGMP manufacture of drug product for clinical trials. With depth and breadth of therapeutic expertise in small and large molecule discovery, development and scale up, combined with unique technology platforms such as high content 3D drug screening, in-vivo translational models, and bioavailability enhancement of insoluble compounds, BioDuro is well positioned to help biopharmaceutical partners significantly accelerate their lead discovery programs, and de-risk development programs for higher value outcomes. Visit www.bioduro.com.